The question bank is the fastest way to start, but PMHNP Helper also includes board-review planning, student resources, and plain-English guidance for psychiatric nurse practitioner students who are still learning the exam landscape.
A 48-year-old female with major depressive disorder and comorbid fibromyalgia was started on duloxetine 60 mg daily ten weeks ago. Her baseline PHQ-9 was 21 and her Brief Pain Inventory (BPI) average pain severity score was 7.2 out of 10. At today's visit, her PHQ-9 is 12 and her BPI average pain severity score is 5.8. She reports improved mood, motivation, and energy, but continues to endorse significant widespread musculoskeletal pain, fatigue, and nonrestorative sleep. She rates the overall change in her condition as minimally improved. Her blood pressure is 128/82 mmHg, up from a baseline of 118/76 mmHg. She denies nausea, headaches, or urinary hesitancy. The PMHNP is evaluating the dual efficacy of duloxetine for both conditions. Which of the following best represents the appropriate evaluation?
Explanation
Evaluating SNRI dual efficacy for comorbid pain and depression requires assessing each domain with appropriate outcome measures and clinical benchmarks. The 30% pain reduction threshold is the standard for clinically meaningful improvement, and differential response between mood and pain domains at lower doses reflects the dose-dependent pharmacology of duloxetine's serotonergic and noradrenergic effects.
Key Takeaway
When evaluating duloxetine for comorbid depression and pain, a greater mood response than pain response at 60 mg may indicate that dose escalation is needed to enhance noradrenergic descending pain inhibition, and a 30% pain reduction threshold should be used to determine clinically meaningful analgesic response.